Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satsuma and SNBL Receive FDA Acceptance for NDA Resubmission of STS101 for Migraine
Details : STS101 (dihydroergotamine nasal powder). STS101 is an investigational product which is being evaluated for migraine with or without aura in adults.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satsuma Resubmits NDA for STS101 Nasal Powder for Migraine Treatment
Details : STS101 (dihydroergotamine nasal powder). STS101 is an investigational product which is being evaluated for migraine with or without aura in adults.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2024
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Declines to Approve Shin Nippon Biomedical's Migraine Drug
Details : STS101 (dihydroergotamine nasal powder). STS101 is an investigational product which is being evaluated in phase 1 clinical trials for the acute treatment of migraine with or without aura in adults.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2024
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STS101 (dihydroergotamine mesylate) constricts the pain-producing intracranial extracerebral blood vessels at the 5-HT1B receptors and inhibiting the trigeminal neurotransmission at the peripheral and central 5-HT1D receptors.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2023
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : SNBL
Deal Size : Undisclosed
Deal Type : Acquisition
SNBL to Acquire Satsuma Pharmaceuticals
Details : The acquisition will expand SNBL's pipeline by including STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 16, 2023
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : SNBL
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Details : STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and inject...
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Subjects administered STS101 (dihydroergotamine mesylate) to treat their migraine attacks for as long as 18 months in a real-world setting, confirm the favorable safety and tolerability profile of STS101 observed to date in more than 1,600 clinical trial...
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2022
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STS101 (dihydroergotamine mesylate) is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.
Product Name : STS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable